Cequa (ciclosporin 900 μg/mL) eye drops are a formulation of ciclosporin indicated to increase tear production in patients with moderate-to-severe keratoconjunctivitis sicca (dry eye), where prior use of artificial tears has not been sufficient.1
Cequa is Pharmaceutical Benefits Scheme listed under authority criteria for chronic severe dry eye disease with keratitis.2
Cequa has been engineered using unique nanomicelle technology to deliver ciclosporin where it’s needed most2-5 and has been found to significantly reduce corneal staining at 28 days vs vehicle (p<0.01).2
Patient starter packs of Cequa are available containing 10 ampoules.
Contact: Sun Pharma (AUS) 1800 726 229
Please review product information before prescribing available from ebs.tga.gov.au, from Sun Pharma or on page 83 of this issue of mivision.
References
- Cequa Approved Product Information.
- Pharmaceutical Benefits Scheme (pbs.gov.au).
- Goldberg DF, et al., doi: 10.1016/j.ophtha.2019.03.050.
- Tauber J et al. doi: 10.2147/OPTH.S175065.
- Vaishya R et al. doi: 10.1002/wnan.1272.
- Weiss SL et al. doi: 10.1089/jop.2018.0106. Date of preparation: July 2024 CEQ2024/07MV.
